Core Insights - The company has made significant progress in business expansion, product development, and market performance, particularly in the solid-state battery materials sector and lithium battery electrolyte additives [1] Business Development - The company has established a joint venture, Sichuan Luocheng New Materials Technology Co., Ltd., with Sichuan Saike Power to promote the research and industrialization of solid-state battery adhesives and other new energy materials, currently in small-scale or pilot testing [2] - The company is investing in a production capacity of 5,000 tons per year for lithium battery electrolyte additives, with the VC project in preparation for production [2] Product Development - The core product, injectable Labetalol Hydrochloride (including new specifications), successfully renewed its contract and was included in the national medical insurance directory as of December 2025 [3] - New drugs such as Aclidinium Bromide capsules and Sodium Thiosulfate injection were approved in 2025, indicating successful consistency evaluation [3] - The company has also applied for production approval for Acetate Cetrorelix injection, which is currently under review [3] Financial Performance - The company's Q3 2025 report shows revenue of 472 million yuan, a year-on-year increase of 30.80%, and a net profit of 32.68 million yuan, up 16.22% year-on-year, with growth in both revenue and net profit for the third quarter [4] Stock Performance - As of January 16, 2026, the company's stock price increased by 3.26% over the week, with a net inflow of 43.65 million yuan from major funds, indicating active trading [5] - The stock price experienced a limit-up on November 14, 2025, driven by solid-state battery concepts and performance catalysts, highlighting significant divergence between retail and institutional investors [5] Company Status - By the end of Q3 2025, new institutional investors, such as Zhongou Yuexiang Life Mixed Fund, entered the top ten circulating shareholders, reflecting increased investor interest [6] - The number of shareholders showed a slight concentration trend by the end of 2025 [6]

Core Viewpoint - Haicheng Pharmaceutical has received approval from the National Medical Products Administration for the registration of Aximol capsules, which are indicated for patients with high triglyceride levels who do not respond adequately to other treatments [1] Group 1: Product Approval - The product Aximol is approved for use as a replacement or adjunct therapy to lower triglyceride levels in patients [1] - It is specifically indicated for Fredrickson Type IV hyperlipoproteinemia and Fredrickson Type IIb hyperlipoproteinemia [1] - The medication is to be used after dietary changes and other non-drug treatments, such as exercise and weight loss, have been attempted [1]

Group 1 - The core point of the article is that Haichen Pharmaceutical has received approval from the National Medical Products Administration for its product "Aximol" capsules [1] - Haichen Pharmaceutical's revenue composition for the year 2024 is entirely from the pharmaceutical manufacturing industry, accounting for 100.0% [2] - As of the latest report, Haichen Pharmaceutical has a market capitalization of 6.4 billion yuan [3] Group 2 - The article highlights that Chinese innovative drugs have generated $80 billion in overseas licensing this year, indicating a robust market for biopharmaceuticals [3] - There is a contrast noted between the hot secondary market for biopharmaceuticals and the cooling fundraising environment in the primary market [3]